F8-IL10: A New Potential Antirheumatic Drug Evaluated by a PET-Guided Translational Approach

Authors:

Abstract
Antibody fragment F8- mediated Interleukin 10 (IL10) delivery is a novel treatment for rheumatoid arthritis (RA). F8 binds to the extra-domain-A of fibronectin (ED-A). In this study, in-vivo biodistribution and arthritis targeting of radiolabeled F8-IL10 were investigated in RA patients, followed by further animal studies. Therefore, three RA patients (DAS28 >3.2) received 0.4 mg, 30-74 megabecquerel [124I]I-F8-IL10 for PET-CT and blood sampling. In visually identified PET-positive joints target-to-background were calculated. Healthy mice, rats, and arthritic rats were injected with iodinated F8-IL10 or KSF-IL10 control antibody. Various organs were excised, weighed and counted for radioactivity. Tissue sections were stained for fibronectin ED-A. In RA patients, [124I]I-F8-IL10 was cleared rapidly from the circulation with less than 1% present in blood after 5 minutes. PET-CT showed targeting in 38 joints (11-15 per patient) and high uptake in liver and spleen. Mean target-to-background ratios of PET-positive joints were 2.5±1.2, and 1.5 times higher for clinically active than clinically silent joints. Biodistribution of radioiodinated F8-IL10 in healthy mice showed no effect of radioiodination method. [124I]I-F8-IL10 joint uptake was also demonstrated in arthritic rats, ~14 fold higher than control antibody [124I]I-KSF-IL10 (p< 0.001). Interestingly, liver and spleen uptake was twice as high in arthritic than in healthy rats and was related to increased (~7x) fibronectin ED-A expression in these tissues. In conclusion, [124I]I-F8-IL10 uptake was observed in arthritic joints in RA patients holding promise for visualization of inflamed joints by PET-CT imaging and therapeutic targeting. Patient observations and subsequently arthritic animal studies pointed to awareness of increased [124I]I-F8-IL10 uptake in liver and spleen associated with moderate systemic inflammation. This translational study demonstrated the value of in vivo biodistribution and PET-CT guided imaging in development of new and potential anti-rheumatic drugs’.
Funding Information
  • FP7 Health

This publication has 36 references indexed in Scilit: